Targeting the TIGIT-PVR immune checkpoint axis as novel therapeutic option in breast cancer

Immune checkpoints are intensively investigated as targets in cancer therapy. T-cell immunoreceptor with immunoglobulin (Ig) and ITIM domains (TIGIT) and its ligand poliovirus receptor (PVR) are recently emerging as novel promising targets in immunotherapy. Here, we show that high expression of PVR...

Descrición completa

Detalles Bibliográficos

Principais autores:	Hauke Stamm, Leticia Oliveira-Ferrer, Eva-Maria Grossjohann, Jana Muschhammer, Vanessa Thaden, Franziska Brauneck, Roman Kischel, Volkmar Müller, Carsten Bokemeyer, Walter Fiedler, Jasmin Wellbrock
Formato:	Artigo
Idioma:	Inglês
Publicado:	Taylor & Francis Group 2019-12-01
Series:	OncoImmunology
Assuntos:	tigit pvr immunotherapy breast cancer
Acceso en liña:	http://dx.doi.org/10.1080/2162402X.2019.1674605
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!